Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.70    0.05 (1.08%)
Bid:
4.70
Ask:
4.70
Spread: 0.00 (0.00%)
Market Cap: £223.18m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Grant Approval

14 Aug 2006 10:57

Seeing Machines Limited14 August 2006 14 August 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") AUSTRALIAN GOVERNMENT APPROVES GRANT APPLICATION Seeing Machines Limited (AIM: SEE), a leading developer of advanced computerbased imaging software systems, has been advised by AusIndustry that itsapplication for an Australian Federal Government Commercial Ready Grantsupporting its glaucoma diagnostic device development project has been approved,conditional on finalising normal contractual arrangements. The grant providesmatching funding of up to AUD$2.1 million over 2 years to support the continueddevelopment and commercialization of the glaucoma device. Seeing Machines' glaucoma device is a non-contact objective device designed toreliably and quickly measure a person's functional visual field. Assessingvisual field is crucial in diagnosing a range of human visual system diseases,such as glaucoma. The key advantages the Seeing Machines device has over thoseavailable on the market today are derived from the objectivity of the technique.It is non-contact, fast and greatly enhances the patient experience. Seeing Machines completed an initial research and development project for thedevice in February 2006 and this work was supported by a $250,000 AusIndustryBiotechnology Innovation Fund Grant. The company has successfully completed(June 2006) a $3.2 million R&D Start Grant project aimed at developing SeeingMachines' face and eye tracking technology to a level where deployment in theautomotive domain for the detection of fatigue and distraction is feasible. Seeing Machines CEO Nick Cerneaz said: "the Company was very pleased to beawarded the Commercial Ready Grant. The strong endorsement of our technology, R&D capabilities and the potential for successful commercialisation of thisdevice is very encouraging." He also commented on the importance of governmentprograms supporting innovation for local industry development and noted thestrong support the company had received over the years for its R&D both fromCommonwealth and local government programs. Federal Industry Minister Ian Macfarlane congratulated Seeing Machines on beingoffered the Australian Government Commercial Ready grant to develop the devicethat will make it easier to diagnose diseases affecting vision: "Diseases such as glaucoma afflict millions of people world-wide and it isdifficult to detect. Seeing Machines has a strong track record in developingtechnology in this field and the Government, through the Commercial Readyprogram, is pleased to support projects such as this." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen Communications Nick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th May 20267:00 amRNSUS$3.8m Order for Guardian BdMS
6th May 20267:00 amRNSQ3 FY2026 Quarterly KPIs
20th Apr 202612:30 pmRNSHolding(s) in Company
10th Apr 20268:53 amRNSStatement re alleged cyber threat
27th Mar 20267:00 amRNSHalf-year Financial Report
24th Feb 20267:00 amRNS-RPublication of Investor Presentation
18th Feb 20267:00 amRNSTrading Update - H1 FY2026
13th Feb 20267:30 amRNSAppointment of Joint Broker
11th Feb 20267:00 amRNSQ2 FY2026 Quarterly KPIs
13th Jan 202612:00 pmRNS-R3D Cabin Perception Mapping breaks new ground
6th Jan 20267:00 amRNSAgreement
5th Jan 20267:00 amRNS-R3D Cabin Perception Mapping to be unveiled at CES
5th Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
17th Dec 20257:00 amRNS-RTechnical Paper Series - Intoxication launched
4th Dec 20257:00 amRNS-RSeeing Machines 2025 Guardian Insights Report
27th Nov 20257:00 amRNSResults of AGM
26th Nov 20257:30 amRNSJapanese Auto Award and Extended European Program
12th Nov 20257:05 amRNSQ1 FY2026 Quarterly KPIs
12th Nov 20257:00 amRNSGuardian order from US-based multinational company
6th Nov 20257:05 amRNS-RCollaboration with Magna milestone in China
3rd Nov 20257:00 amRNSBoard Changes
3rd Nov 20257:00 amRNSNotice of Annual General Meeting
30th Oct 20257:00 amRNSLATAM Distributor Orders 1,300 Guardian Units
29th Oct 20257:00 amRNSAdvanced Development Project with Japanese OEM
8th Oct 20257:00 amRNSUS$1.8m expansion order for Guardian BdMS
26th Sep 20257:00 amRNSExpanding Guardian prospects across Europe
25th Sep 20257:00 amRNSFY2025 Results and Annual Financial Report
24th Sep 20257:20 amRNSFirst Guardian contract through Mitsubishi
10th Sep 20257:05 amRNS-RSeeing Machines Launches Impairment Capability
10th Sep 20257:00 amRNSNotice of Results and Presentation
29th Aug 202510:10 amRNSDirector Dealing
21st Aug 20257:00 amRNSFY2025 Trading Update
5th Aug 20257:00 amRNSQ4 FY2025 Quarterly KPIs
30th Jun 20257:00 amRNSMitsubishi Electric Europe Guardian collaboration
27th Jun 20257:00 amRNSUS Guardian Gen 3 trial with Mitsubishi Electric
16th Jun 20258:59 amRNS$1.2 Million Agreement with Global Auto Leader
9th May 20252:31 pmRNSDirector dealing
1st May 20257:00 amRNSQ3 FY2025 Quarterly KPIs
29th Apr 20259:58 amRNSNotification of Major Holdings
8th Apr 20258:53 amRNSHoldings in Company
8th Apr 20257:00 amRNSDirector/PDMR Shareholding
4th Apr 20257:00 amRNSDirector dealing
2nd Apr 202511:00 amRNSLondon presentation for investors and analysts
2nd Apr 20257:00 amRNSDirector dealing
2nd Apr 20257:00 amRNSDirector dealing
1st Apr 202512:00 pmRNS-RSeeing Machines Announces 3D Camera Technology
31st Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.